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 ORIGINAL ARTICLE 
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Health, University of Manitoba, Winnipeg MB, Canada,  5 Department of Epidemiology, Erasmus University Medical 
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 Abstract 
 Objective . To determine how often patients with musculoskeletal (MSK) complaints prescribed a non-steroidal anti-infl am-
matory drug (NSAID) subsequently consult their general practitioner (GP) with a non-serious adverse drug reaction 
(ADR).  Design . Cohort study.  Setting . A healthcare database containing the electronic GP medical records of over 1.5 mil-
lion patients throughout the Netherlands.  Patients . A total of 16 626 adult patients with MSK complaints prescribed an 
NSAID.  Main outcome measures . The patients ’ medical records were manually assessed for the duration of NSAID use for 
a maximum of two months, and consultations for complaints predefi ned as potential ADRs were identifi ed. Subsequently, 
the likelihood of an association with the NSAID use was assessed and these potential ADRs were categorized as likely, 
possible, or unlikely ADRs.  Results . In total, 961 patients (6%) consulted their GP with 1227 non-serious potential ADRs. 
In 174 patients (1%) at least one of these was categorized as a likely ADR, and in a further 408 patients (2.5%) at least 
one was categorized as a possible ADR. Dyspepsia was the most frequent likely ADR, followed by diarrhoea and dyspnoea 
(respectively 34%, 8%, and 8% of all likely ADRs).  Conclusion . Of the patients with MSK complaints prescribed an NSAID, 
almost one in 30 patients re-consulted their GP with a complaint likely or possibly associated with the use of this drug. 
The burden of such consultations for non-serious ADRs should be taken into account by GPs when deciding whether 
treatment with an NSAID is appropriate. 
 Key Words:  Anti-infl ammatory agents ,  drug toxicity ,  general practice ,  musculoskeletal/connective tissue ,  non-steroidal , 
 pharmacoepidemiology ,  primary health care ,  The Netherlands 
adverse drug reactions (ADRs), ranging from mild 
complaints to serious complications, particularly of 
the gastrointestinal (GI), cardiovascular, and renal 
tract [3 – 8]. Over the past few decades, many studies 
have focused on the occurrence of serious ADRs 
due to NSAIDs, and on related hospitalizations and 
death [3 – 9]. However, less is known about the 
incidence of non-serious ADRs due to NSAIDs in 
 Introduction 
 Musculoskeletal (MSK) complaints are the most 
commonly presented complaints in the primary care 
population [1]. In around one-quarter of consulta-
tions for these MSK complaints, the general 
practitioner (GP) prescribes a non-steroidal anti-
infl ammatory drug (NSAID) [2]. The use of these is 
known to be associated with the occurrence of 
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 A. R. Koffeman et al. 
the primary care population and in resulting health 
care utilization in the form of GP consultations. One 
previous study that did focus specifi cally on primary 
care patients found that 40% of chronic NSAID 
users suffering from gastrointestinal complaints 
consulted their GP for these complaints [10]. 
Whether other types of adverse events also lead to 
consultation and how frequently such consultations 
occur in short-term NSAID users is not known. In 
this cohort study, we aim to determine how often 
patients with an MSK complaint newly treated with 
an NSAID by their GP subsequently consult their 
GP because of an adverse drug reaction. 
 Materials and methods 
 Setting 
 This study was conducted in the Integrated Primary 
Care Information (IPCI) database. This Dutch pri-
mary health care database contains the electronic 
patient records of more than 1.5 million patients. In 
the Netherlands, all citizens are registered with one 
GP, who forms the fi rst point of care for all medical 
complaints. The electronic medical records contain 
all journal entries written by the GPs, and coded and 
anonymous data on patient demographics, diagnoses 
using the International Classifi cation for Primary 
Care (ICPC) [11], referrals, laboratory fi ndings, and 
drug prescriptions. Further details of the database 
have been described elsewhere [12,13]. 
 Patients 
 The study population comprised all patients    18 
years newly prescribed an NSAID because of a MSK 
complaint between 1 January 2010 and 1 July 2010, 
with at least a 12-month valid database history prior 
to the date of study entry. Excluded were patients 
who had been prescribed an NSAID in the six 
months prior to study entry and patients without suf-
fi cient follow-up time in the IPCI database. Diagno-
ses of MSK complaints were identifi ed based on 
ICPC coding and were considered new if the patient 
had not been diagnosed with the same MSK 
complaint in the six months prior to consultation. 
Only patients who received an NSAID prescription, 
identifi ed by Anatomical Therapeutic Chemical 
(ATC) code [14], on the day of a consultation for 
the MSK complaint were included. 
 Manual assessment of electronic medical records 
 The electronic medical record of all included patients 
was manually assessed for the duration of continuous 
NSAID use for a maximum of two months. 
Continuous use was defi ned as use of NSAIDs with 
treatment gaps of no more than 10% of the previous 
prescription duration. This means that the medical 
records were assessed for the duration of the fi rst 
NSAID prescription, as well as any follow-up 
prescriptions (if issued), provided the treatment 
gap between these prescriptions was no more than 
10%, with an overall maximum of two months. 
 Consultations for adverse drug reactions 
 The aim of this manual assessment was to determine 
whether the patient consulted his/her GP with an 
ADR likely or possibly associated with the NSAID 
treatment. To achieve this, the following stepwise 
approach was used: 
  • Step 1:  Identifi cation of potential ADRs . First, any 
consultations for complaints that may poten-
tially be an ADR were identifi ed. We predefi ned 
the complaints that should be considered a 
 “ potential ADR ” based on listed common 
NSAID-related adverse drug reactions. All clin-
ical complaints listed as common ADRs for at 
least two types of NSAID were included [15]. 
In addition to these, angio-oedema and signs of 
gastrointestinal bleeding were also included 
because, although rare, they are listed for all 
types of NSAIDs. As a result, the following 13 
complaints were predefi ned as potential ADRs: 
skin reactions, dyspepsia, diarrhoea, constipa-
tion, peripheral oedema, dyspnoea (including 
wheezing), headache, dizziness, drowsiness, 
angio-oedema, hematemesis, black stool, and 
rectal bleeding. If a patient consulted his/her 
GP with a complaint that was not predefi ned as 
a potential ADR but which the patient attrib-
uted to the use of NSAIDs, this was also 
recorded. If the GP recorded the occurrence of an 
ADR, without specifying the type of complaint 
 General practitioners (GPs) frequently treat  •
musculoskeletal complaints with non-steroidal 
anti-infl ammatory drugs (NSAIDs). 
 In this study, it was found that one in 30  •
patients prescribed an NSAID by their GP 
for a musculoskeletal complaint subsequently 
consult their GP with a likely or possible 
ADR. 
 In addition to the risk of serious but rare  •
ADRs, GPs should take this occurrence of 
non-serious ADRs into account when decid-
ing whether treatment with an NSAID is 
appropriate. 
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  ADRs in primary care patients prescribed NSAIDs   
presented, these unspecifi ed ADRs were also 
recorded. 
  • Step 2: Categorization of potential ADRs as likely, 
possibly or unlikely to be associated with the NSAID 
use. We then estimated the likelihood that a 
potential ADR which led to GP consultation 
was indeed associated with the use of the 
NSAID. In order to assess this, we read the GP ’ s 
journal entry and recorded whether: (1) the GP 
explicitly recorded the NSAID as the cause of 
the potential ADR; (2) the GP explicitly discon-
tinued the NSAID; (3) the GP recorded an 
alternative diagnosis as the cause of the poten-
tial ADR; and (4) the patient had consulted 
his/her GP for the same complaint as the 
potential ADR in the six months prior to study 
entry. Based on these four criteria, potential 
ADRs were subsequently categorized as likely, 
possible, or unlikely ADR according to the 
algorithm shown in Figure 1. 
 Predictors of consultation for a likely ADR 
 To determine whether any predictive factors for con-
sultation with a likely ADE could be identifi ed, we 
compared patients who consulted their GP because 
of a likely ADR with those without a consultation. In 
addition to age and gender, concomitant prescription 
of a gastroprotective agent (GPA) was determined. 
This was defi ned as concomitant use of a proton 
pump inhibitor (PPI), double-dosed histamine-2 
receptor antagonist (H2RA), or misoprostol, on the 
day of fi rst NSAID prescription. In addition, the 
NSAID prescribed was classifi ed as a non-selective 
NSAID (nsNSAID) or a selective cox-2 inhibitor 
(coxib) based on ATC coding. 
 Statistical analyses 
 The incidence rate of consultations for potential 
ADRs was calculated by dividing the number of 
consultations for potential ADRs by the total num-
ber of person-days of NSAID use in the entire 
cohort. This was then multiplied by 1000 to present 
the number of consultations for potential ADRs per 
1000 person-days of NSAID use. The same method 
was used to determine the incidence rate of consul-
tations for likely and possible ADRs. Univariate 
analyses of potential predictors of a likely ADR such 
as age, gender, and type of NSAID were conducted 
and unadjusted odds ratios (ORs) and their 95% 
confi dence intervals (CIs) were calculated by 
performing logistic regression analyses. In order to 
determine ORs adjusted for age and gender, multi-
variate analyses were also performed for the predic-
tor type of NSAID and concomitant prescription of 
GPA. All analyses were performed using SPSS  ™  
version 20 (IBM, Armonk, NY, USA). 
 Results 
 Patients 
 In total, 16 626 adults were newly prescribed an 
NSAID for a MSK complaint and were included in 
this study (Table I). Symptomatic diagnoses of the 
back or neck were the most common indication 
for NSAID treatment. The median duration of 
continuous NSAID treatment was 11 days, with an 
interquartile range of seven days. The most com-
monly prescribed NSAIDs were diclofenac (65%), 
ibuprofen (11%), and naproxen (8%). Coxibs were 
prescribed in 4% of patients. In total, 36% of 
patients were prescribed a concomitant GPA or 
were already using a GPA on the date of NSAID 
prescription. 
GP records predefined potential ADR
OR
GP records other complaint which
patient attributes to use of NSAID
OR
GP records occurrence of ADR without
specifying further
GP records NSAID as cause of
potential ADR
OR
GP discontinues NSAID
Likely ADR
n=216Yes
GP records alternative diagnosis as
cause of potential ADR
OR
Same complaint occurred in 6 months
prior 
No
Yes Unlikely ADR
n=504
Possible ADR
n=507No
Potential ADR
n=1 227
 Figure 1. Assessment algorithm. Notes: GP    general practitioner; 
NSAID    non-steroidal anti-infl ammatory drug; ADR    adverse 
drug reaction.  * Skin reaction, angio-oedema, dyspepsia, diarrhoea, 
constipation, peripheral oedema, dyspnoea, chest pain, headache, 
dizziness, tinnitus, drowsiness, hematemesis, black stool, or rectal 
bleeding. 
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 Consultation for a potential adverse drug reaction and 
likelihood of an association with NSAID use 
 In total, 961 patients (6%) consulted the GP for at 
least one potential ADR (Table II). As 224 patients 
consulted their GP for more than one potential ADR, 
a total of 1227 potential ADRs were reported by 
these 961 patients. The median duration between the 
start of the NSAID and GP consultation for a poten-
tial ADR was seven days, with an interquartile range 
of eight days. The incidence rate was four consulta-
tions for a potential ADR per 1000 person-days of 
NSAID prescription. 
 Table III shows the type of potential ADRs pre-
sented in more detail. The most frequently presented 
potential ADRs were dyspepsia (32%), dyspnoea 
(13%) and skin reactions (12%). As previously 
described and shown in Figure 1, we then assessed 
the likelihood that these potential ADRs were associ-
ated with the use of the NSAID: 
  • Likely ADRs : The GP recorded the NSAID use 
as the cause of the adverse events in 146 cases, 
and discontinued the NSAID in 121 cases. 
Some overlap was present between these two 
criteria, leading to 216 potential ADRs (18%) 
being categorized as likely. This corresponds 
with an incidence rate of one potential ADR 
presented per 1000 person-days of NSAID 
prescription. 
  • Unlikely ADRs : In 452 cases, the GP recorded an 
alternative diagnosis as the cause of the potential 
ADR and in 248 cases the patient had presented 
the same complaint as the potential ADR in 
the six months prior, resulting in 504 potential 
ADRs being categorized as unlikely ADRs 
(again, overlap between criteria was present). 
  • Possible ADRs : The remaining 507 adverse events 
presented (41%) were categorized as possible 
ADRs. 
 The incidence rate of likely and possible ADRs com-
bined was three per 1000 person-days of NSAID 
prescription. 
 Predictors of consultation for a likely ADR 
 In total, 174 patients, or 1% of the total cohort, con-
sulted the GP for at least one likely ADR (Table IV). 
Of those patients in whom no likely ADR occurred, 
408 patients (2.5%) presented at least one possible 
ADR. When compared with patients who did not re-
consult the GP for an adverse event, GP consultation 
for a likely ADR was more frequent in elderly patients, 
in women, and in those prescribed a coxib or con-
comitant GPA. 
 Discussion 
 Statement of principal fi ndings 
 In this study, we aimed to provide an insight into the 
incidence of GP consultation for non-serious ADRs, 
 Table I. Baseline characteristics of the study population. 
No. of 
patients
 n    16 626
Age in years, mean (   SD) 50.9 (   15.7)
Age category, n (%):
18 – 35
 36 – 50
 51 – 65
    65
2 918 (17.6)
 5 670 (34.1)
 5 108 (30.7)
 2 930 (17.6)
Female, n (%) 8 950 (53.8)
Musculoskeletal complaint diagnosed, n (%):
Symptomatic diagnosis 11 397 (68.5)
Back or neck
 Upper extremity
 Lower extremity
 Generalized/other
4 155 (25.0)
 3 540 (21.3)
 2 107 (12.7)
 1 595 (9.6)
Arthritis 1 283 (7.7)
Infl ammatory arthritis
 Osteoarthritis
 Gout
201 (1.2)
 442 (2.7)
 640 (3.8)
Radiculopathy
 Trauma
 Other
1 165 (7.0)
 765 (4.6)
 2 016 (12.1)
Type of NSAID prescribed, n (%):
Non-selective NSAID 16 041 (96.5)
Diclofenac
 Ibuprofen
 Naproxen
 Other
10 799 (65.0)
 1 800 (10.8)
 1 382 (8.3)
 2 060 (12.4)
Coxib 585 (3.5)
Celecoxib
 Etoricoxib
170 (1.0)
 415 (2.5)
Duration of NSAID prescription in days, 
median (IQR)
11.0 (7.0)
Concomitant GPA prescribed, n (%) 6 032 (36.3)
 Notes: NSAID    non-steroidal anti-infl ammatory drug; coxib   
 selective cox-2 inhibitor; 
 IQR    interquartile range; GPA    gastroprotective agent. 
 Table II. Consultation for a potential ADR. 
No. of 
patients
 n    16 626
At least one consultation for a potential ADR, n (%) 961 (5.8)
Duration since start NSAID in days, median (IQR) 7.0 (8.0)
Number of potential ADR reported per patient, n (%):
1
 2
 3
 4
 5
743 (4.5)
 184 (1.1)
 34 (0.2)
 4 (0.02)
 2 (0.01)
 Notes: ADR    adverse drug reaction; NSAID    non-steroidal 
anti-infl ammatory drug; IQR    interquartile range. 
 A. R. Koffeman et al. 166
D
ow
nl
oa
de
d 
by
 [E
ras
mu
s U
niv
ers
ity
] a
t 0
4:5
7 1
8 J
an
ua
ry
 20
16
 
    
among primary care patients prescribed an NSAID 
by their GP because of MSK complaints. We found 
that almost one in 30 patients treated with NSAIDs 
for a median duration of 11 days consulted their GP 
with a complaint that was likely or possibly an ADR. 
The incidence rate of consultations for such likely 
and possible ADRs combined was three per 1000 
person-days of NSAID prescription. Elderly and 
female patients were more likely to consult their GP 
because of a likely ADR, which may refl ect the fact 
that such patients are generally more likely to consult 
their GP [1]. Patients prescribed coxibs or an nsN-
SAID with concomitant GPA were also most likely 
to present a likely ADR, which is probably due to 
confounding by indication. These results do indicate, 
however, that such gastroprotective strategies do not 
fully protect against the occurrence of non-serious 
ADRs in patients prescribed NSAIDs. 
 Table III. Types of potential ADRs presented to GP and likelihood of an association with NSAID use. 
Potential ADR Assessment criteria † Likelihood of an association with NSAIDs ‡ 
Type
Number
 n    1 227
 n (%)
GP records 
 NSAID as 
 cause
 n    146
 n (%)
GP discontinues 
NSAID
 n    121
 n (%)
GP records 
alternate 
diagnosis
 n    452
 n (%)
Same complaint
 in 6 months 
 prior
 n    248
 n (%)
Likely ADR
 n    216
 n (%)
Possible ADR
 n    507
 n (%)
Unlikely ADR
 n    504
 n (%)
Not specifi ed 39 (3.2) 39 (26.7) 6 (5.0) 0 (0) 0 (0) 39 (18.1) 0 (0) 0 (0)
Not predefi ned 38 (3.1) 5 (3.4) 7 (5.8) 7 (1.5) 4 (1.6) 9 (4.2) 21 (4.1) 8 (1.6)
Skin reaction 142 (11.6) 10 (6.8) 6 (5.0) 100 (22.1) 31 (12.5) 13 (6.0) 26 (5.1) 103 (20.4)
Angio-oedema 28 (2.3) 8 (5.5) 7 (5.8) 12 (2.7) 6 (2.4) 10 (4.6) 5 (1.0) 13 (2.6)
Dyspepsia 398 (32.4) 39 (26.7) 51 (42.1) 83 (18.4) 78 (31.5) 73 (33.8) 208 (41.0) 117 (23.2)
Diarrhoea 104 (8.5) 13 (8.9) 10 (8.3) 22 (4.9) 14 (5.6) 17 (7.9) 60 (11.8) 27 (5.4)
Constipation 53 (4.3) 1 (0.7) 0 (0) 12 (2.7) 13 (5.2) 1 (0.5) 32 (6.3) 20 (4.0)
GI blood loss * 37 (3.0) 9 (6.2) 8 (6.6) 13 (2.9) 4 (1.6) 14 (6.5) 10 (2.0) 13 (2.6)
Oedema 57 (4.6) 5 (3.4) 8 (6.6) 16 (3.5) 15 (6.0) 10 (4.6) 26 (5.1) 21 (4.2)
Dyspnoea 153 (12.5) 12 (8.2) 6 (5.0) 90 (19.9) 49 (19.8) 17 (7.9) 32 (6.3) 106 (21.0)
Headache 57 (4.6) 1 (0.7) 2 (1.7) 34 (7.5) 14 (5.6) 3 (1.4) 19 (3.7) 35 (6.9)
Dizziness 82 (6.7) 2 (1.4) 7 (5.8) 29 (6.4) 20 (8.1) 9 (4.2) 36 (7.1) 37 (7.3)
Drowsiness 39 (3.2) 2 (1.4) 3 (2.5) 5 (1.1) 0 (0) 3 (1.4) 32 (6.3) 4 (0.8)
 Notes: ADR    adverse drug reaction; GP    general practitioner; NSAID    non-steroidal anti-infl ammatory drug; GI    gastrointestinal. 
 * Hematemesis, melena or rectal bleeding.  † Criteria can overlap.  ‡ According to assessment algorithm.\ 
 Table IV. Predictors of consultation for a likely ADR. 
Consultation
At least one 
likely ADR
 n    174
 n (%)
At least one 
possible ADR * 
 n    408
 n (%)
At least one 
unlikely ADR * * 
 n    379
 n (%)
No consultation
 n    15 665
 n (%)
OR
 (95% CI)
 Likely ADR
 vs. no consultation
Adjusted OR † 
 (95% CI)
 Likely ADR
 vs. no consultation
Age category:
18 – 35
 36 – 50
 51 – 65
    65
37 (21.3)
 49 (28.2)
 36 (20.7)
 52 (29.9)
53 (13.0)
 137 (33.6)
 108 (26.5)
 110 (27.0)
54 (14.2)
 110 (29.0)
 110 (29.0)
 105 (27.7)
2 774 (17.7)
 5 374 (34.3)
 4 854 (31.0)
 2 663 (17.0)
1 (ref.)
 0.7 (0.4 – 1.1)
 0.6 (0.4 – 0.9)
 1.5 (1.0 – 2.2)
 – 
 – 
 – 
 – 
Gender:
Male
 Female
59 (33.9)
 115 (66.1)
131 (32.1)
 277 (67.9)
137 (36.1)
 242 (63.9)
7 349 (46.9)
 8 316 (53.1)
1 (ref.)
 1.7 (1.3 – 2.4)
 – 
 – 
Type of NSAID:
Non-selective NSAID 162 (93.1) 392 (96.1) 355 (93.7) 15 132 (96.6) 1 (ref.) 1 (ref.)
Coxib 12 (6.9) 16 (3.9) 24 (6.3) 533 (3.4) 2.1 (1.2 – 3.8) 1.9 (1.1 – 3.5)
Concomitant GPA prescribed:
None
 PPI
 H2RA in double dosage
 Misoprostol
82 (47.1)
 67 (38.5)
 0 (0.0)
 25 (14.4)
227 (55.6)
 142 (34.8)
 0 (0.0)
 39 (9.6)
214 (56.5)
 135 (35.6)
 0 (0.0)
 30 (7.9)
10 071 (64.3)
 4 231 (27.0)
 3 (0.0)
 1 350 (8.7)
1 (ref.)
 1.9 (1.4 – 2.7)
 – 
 2.3 (1.4 – 3.5)
1 (ref.)
 1.8 (1.3 – 2.6)
 – 
 2.2 (1.4 – 3.5)
 Notes: ADR    adverse drug reaction; NSAID    non-steroidal anti-infl ammatory drug; coxib    selective cox-2 inhibitor; 
 GPA    gastroprotective agent; PPI    proton pump inhibitor; H2RA    histamine-2 receptor antagonist.  * And no likely ADR.  * * And 
no likely or possible ADR.  † Adjusted for age and gender. 
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 Strengths and weaknesses of the study 
 When interpreting the results, there are some limita-
tions to be taken into account. First, as the data were 
obtained from the medical journals, some information 
relevant to this study, such as verbal advice given to 
the patient regarding a complaint, may have been 
missed. This would result in an underestimation of the 
occurrence of adverse drug reactions reported to the 
GP. In addition, we were unable to apply existing cau-
sality assessment methods, such as the algorithms by 
Kramer or Naranjo, or the WHO-UMC causality 
assessment system [16 – 18]. Our assessment of the 
likelihood that an ADR was associated with the NSAID 
use was based on the opinion of the treating GP as 
documented in the medical journal, or, if no informa-
tion was recorded, on the GP ’ s active discontinuation 
of the NSAID as a proxy. Again, the true number of 
ADRs is likely to be higher, as GPs may fail to take the 
use of the NSAID into account when assessing the 
cause of a complaint, or refrain from recording their 
considerations. Second, we had no information on the 
use of over-the-counter NSAIDs. Included patients 
were prescribed an NSAID by their GP, those patients 
not prescribed an NSAID but using NSAIDs over-the-
counter were therefore not included in this study. 
 Strengths and weaknesses in relation to other studies 
 One previous study focusing on gastrointestinal com-
plaints in primary care patients found that, of 1014 
included chronic NSAID users, 185 had consulted 
their GP because of a gastrointestinal complaint in 
the past year (incidence rate 0.5 per 1000 person-
days) [10]. As this study included only chronic 
NSAID users who had used NSAIDs for at least nine 
months, patients particularly prone to gastrointestinal 
symptoms while taking NSAIDs would have been 
 “ selected out ” and not formed part of the study pop-
ulation. The strength of our study is that we included 
and followed up all new NSAID users, which may 
explain the higher consultation rate for gastrointesti-
nal and other adverse events found. Another study 
performed in Italy included 1842 patients who were 
treated by their GP with ibuprofen [19]. During the 
follow-up of 30 days, ADRs were found to occur in 
14% of patients (incidence rate 4.7 per 1000 person-
days). Although these results are of interest, the 
generalizability to the total primary care population 
remains unclear, as the methods for recruiting patients 
and the inclusion criteria were not reported. 
 Meaning of the study 
 The majority of patients in our study were treated 
with NSAIDs for symptomatic complaints of the 
musculoskeletal system, which are often self-limiting 
in nature. Indeed, the median duration of NSAID 
prescription in these patients was only 11 days and 
almost 60% of patients consulted their GP only once 
for their musculoskeletal complaint. In light of this, 
we feel that GPs should address not only the risk of 
serious ADRs when discussing treatment options for 
MSK complaints with their patients, but also our 
fi nding of re-consultation for non-serious ADRs. 
Although these non-serious ADRs are less harmful 
to the patient, they lead to an increase in primary 
health care utilization and may outweigh the benefi ts 
of NSAID treatment for many patients. 
 Conclusion 
 Of the patients with MSK complaints prescribed an 
NSAID, almost one in 30 patients consulted their 
GP with a complaint likely or possibly associated 
with the use of this drug. The burden of such non-
serious ADRs should be taken into account by GPs 
when deciding whether treatment with an NSAID is 
appropriate. 
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